Lindbrook Capital LLC Buys 411 Shares of Moderna, Inc. (NASDAQ:MRNA)

Lindbrook Capital LLC increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 41.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,391 shares of the company’s stock after acquiring an additional 411 shares during the period. Lindbrook Capital LLC’s holdings in Moderna were worth $138,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of MRNA. IFP Advisors Inc lifted its stake in shares of Moderna by 18.8% in the 3rd quarter. IFP Advisors Inc now owns 834 shares of the company’s stock valued at $86,000 after acquiring an additional 132 shares during the last quarter. Ritholtz Wealth Management lifted its stake in shares of Moderna by 27.1% in the 3rd quarter. Ritholtz Wealth Management now owns 2,122 shares of the company’s stock valued at $219,000 after acquiring an additional 452 shares during the last quarter. HB Wealth Management LLC lifted its stake in shares of Moderna by 49.2% in the 3rd quarter. HB Wealth Management LLC now owns 3,192 shares of the company’s stock valued at $330,000 after acquiring an additional 1,052 shares during the last quarter. Flagship Harbor Advisors LLC lifted its stake in shares of Moderna by 13.1% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 4,537 shares of the company’s stock valued at $469,000 after acquiring an additional 526 shares during the last quarter. Finally, Avior Wealth Management LLC lifted its stake in shares of Moderna by 219.9% in the 3rd quarter. Avior Wealth Management LLC now owns 3,097 shares of the company’s stock valued at $320,000 after acquiring an additional 2,129 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

MRNA has been the subject of a number of recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target for the company in a research report on Tuesday, January 2nd. Canaccord Genuity Group upped their price target on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Finally, HSBC reaffirmed a “reduce” rating and set a $86.00 price target (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $126.49.

Insider Buying and Selling

In related news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the sale, the president now owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Shannon Thyme Klinger sold 544 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the completion of the transaction, the insider now directly owns 9,267 shares in the company, valued at $917,896.35. The disclosure for this sale can be found here. Insiders have sold 109,954 shares of company stock worth $11,533,976 in the last 90 days. Insiders own 15.20% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $107.89 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The stock’s 50 day moving average is $101.39 and its 200 day moving average is $93.53. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $142.79.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm’s quarterly revenue was down 44.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.61 EPS. As a group, sell-side analysts predict that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.